See the DrugPatentWatch profile for Pegfilgrastim
Who owns the pegfilgrastim patent (Teva vs Amgen)?
Pegfilgrastim (a long-acting G-CSF) is widely associated with Amgen’s branded product Neulasta. Teva markets its own pegfilgrastim biosimilar products, but biosimilar launches depend on patent and exclusivity status rather than Teva “owning” the original pegfilgrastim core patent itself.
Because the user query is specific to “Pegfilgrastim Teva patent” but no country, product name (brand/biosimilar), or patent list is provided, the exact patents that apply to a Teva pegfilgrastim product cannot be identified from the question alone.
What patents typically control pegfilgrastim (and biosimilar entry)?
For pegfilgrastim biosimilars, entry timing usually depends on:
- Composition and formulation patents covering pegfilgrastim itself and long-acting delivery (e.g., how the molecule is engineered).
- Method-of-use patents (for example, indications and dosing regimens).
- Patent thickets that can include multiple families filed by the reference manufacturer.
Even if a biosimilar is approved clinically, it can still be delayed by active patents or exclusivity in the target jurisdiction.
How to find the exact “Teva pegfilgrastim” patents for your country
To identify the specific patents relevant to a Teva pegfilgrastim product, you need at least:
- The country (e.g., US, EU, UK, Canada, etc.).
- The exact Teva product name (biosimilar name or brand).
- The regulatory filing type (e.g., FDA biosimilar reference product/label).
Once those are known, the exact patent numbers are typically found via the regulatory patent-linking systems used in each region (for example, the FDA’s patent listings for biologics in the US, or EPI/linked patent registries in other jurisdictions).
When does pegfilgrastim’s exclusivity/patent protection end?
Exact dates vary by jurisdiction and by which patent or exclusivity regime is being asked about (compound, formulation, method-of-use, and regulatory exclusivity can end at different times). Without the country and specific patent family/product, any end date would be guesswork.
What I need to give a precise patent answer
Reply with:
1) The country (or market) you care about (US/EU/UK/Canada/etc.)
2) The Teva pegfilgrastim product name (or whether it’s a biosimilar and its trade name)
3) Whether you want the earliest relevant filing dates, the controlling patents, or the expected end/expiry timeline
With that, I can map the relevant patents and explain what they likely cover for Teva’s pegfilgrastim product.
Sources
No source links were provided in the prompt, so I did not cite any.